Loading...

ASTRAZEN Astrazeneca Pharma India Ltd Product Launches Announcement

strz

STRZ

Astrazeneca Pharma India Ltd

(ASTRAZEN)

2025 Announcement

Show Summary

Summary

Compliance Certificate

Eculizumab Launch

Company Clarification

Annual General Meeting

TDS on Dividend

Regulatory Compliance

New Product Approval

Key Personnel Details

Compliance Certificate

Management Change

Management Change

Financial Results

Financial Results

Secretarial Compliance Report

Secretarial Auditor Appoint...

Financial Results

Product Approval

New Product Approval

New Drug Approval

Compliance Certificate

Product Discontinuation

Tax Order Received

SEBI Compliance Certificate

New Product Approval

Investor Meeting

Product Discontinuation

Tax Relief Update

Income Tax Draft Order

Compliance Certificate

Product Approval

New Drug Approval

Product Launch Approval

E-voting Announcement

Management Appointment

Financial Results Update

Strong Q3 Results

BSE Warning Letter

Management Appointment

Compliance Certificate

Regulatory Warning

Court Ruling Update

Eculizumab Approval

Compliance Certificate

Tax Order Received

Compliance Confirmation

Tax Tribunal Order

New Product Approval

Director Appointments

Product Launch Announcement

Financial Results

Strong Q2 Performance

Q2 2024 Results

Director Appointment

Regulatory Compliance

Management Appointment

Regulatory Compliance

Volume Inquiry Response

New Product Launch

Tremelimumab Launch

Tax Assessment Update

Regulatory Compliance

Management Change

Q2 Financial Results

AstraZeneca Pharma India Lt...

Income Tax Assessment Order

AGM Announcement

Compliance Certificate

TDS Communication

Meeting Intimation

Meeting Intimation

Tax Appeal Order

ITAT Order Disclosure

ITAT Order Received

Senior Management Change

Exploration Conclusion

Compliance Certificate Filing

Appointment of Senior Manag...

Approval of Material Relate...

Financial Results Declaration

Compliance Report Submission

Revenue Growth Announcement

Resignation of Director

Product Discontinuation

Compliance Certificate

Certificate Submission

Certificate Approval

SEBI Compliance Certificate

Annual General Meeting

Regulatory Approval

Appointment of Senior Manag...

Certificate Compliance

Distribution Agreement

Appointment of Director

Meeting Intimation

Senior Management Change

Financial Results Announcement

Directorate Change

Certificate Compliance

Permission Granted

Appointment of Directors

Compliances Certificate

Tax Assessment Order

Appointment of Additional D...

Launch of Trastuzumab Derux...

Compliance Certificate

Permission granted for BREZ...

Appointment of Senior Manag...

Permission Granted for New ...

Exit from Manufacturing Site

Compliance Certificate Subm...

Financial Results

Appointment of Additional D...

Tax Adjustment Order

Compliance Certificate

Increase in Volume

Materiality Determination D...

Import Permission for Paliv...

Appointment of Senior Manag...

Compliances Certificate

Tax-related litigation

New Product Launches

Management Changes

Management Changes

New Product Launches

Annual General Meeting

Communication to Shareholders

Compliance Certificate

New Product Launches

Financial Statements

Key Executive Appointment

Retirement and appointment

Disclosure of Related Party...

Managerial Compliance

New Product Launches

External Links:

Data:

AstraZeneca Pharma India Ltd has surrendered the marketing authorisation for Olaparib (Lynparza) 100mg and 150mg for a specific prostate cancer treatment, which they never marketed since receiving the authorisation on November 17, 2023, due to commercial reasons.

AI Assistant

Astrazeneca Pharma India Ltd

2025

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.